None
Quote | Entera Bio Ltd. Warrant (NASDAQ:ENTXW)
Last: | $0.0012 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.0012 |
High: | $0 |
Low: | $0 |
Volume: | 210 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Entera Bio Ltd. Warrant (NASDAQ:ENTXW)
JERUSALEM, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S. financial markets open on Tuesday, August 20, 2019. The Company will host a c...
JERUSALEM, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz, Ph.D., former CEO of Entera since the Company’s inception in 2010, will ...
Message Board Posts | Entera Bio Ltd. Warrant (NASDAQ:ENTXW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Entera Bio Ltd. Warrant Company Name:
ENTXW Stock Symbol:
NASDAQ Market:
JERUSALEM, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S. financial markets open on Tuesday, August 20, 2019. The Company will host a c...
JERUSALEM, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz, Ph.D., former CEO of Entera since the Company’s inception in 2010, will ...
JERUSALEM, July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three dif...